PedAM

Pediatric Disease Annotations & Medicines


	angioedema

Disease ID	381
Disease	angioedema
Definition	Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.
Synonym	angio edema angio oedema angio oedema urticaria angio-edema angio-oedema angio-oedema-urticaria angioedema (disorder) angioedema [disease/finding] angioedema urticaria angioedema, nos angioedema-urticaria angioedemas angioneurotic edema angioneurotic edema, nos angioneurotic edemas angioneurotic oedema angiooedema bannister disease edema angioneurotic edema quincke's edema, angioneurotic edema, circumscribed edema, quincke's edemas, angioneurotic giant hives giant urticaria giant urticaria (disorder) giant urticarias hives giant milton-quincke giant urticaria quincke edema quincke syndrome quincke's disease quincke's edema quincke's oedema quinckes edema urticaria angioedema urticaria giant urticaria, giant urticaria-angio-oedema urticaria-angioedema urticarias, giant
DOID	DOID:1558 DOID:0060002
UMLS	C0002994
MeSH	D000799
SNOMED-CT	SNOMEDCT_US_2016_09_01:41291007;SNOMEDCT_US_2016_09_01:400075008
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:40) C0042109 \| urticaria \| 24 C0019243 \| c1 inhibitor deficiency \| 16 C0019243 \| hereditary angioedema \| 7 C0157741 \| idiopathic urticaria \| 4 C0011847 \| diabetes \| 3 C0024314 \| lymphoproliferative disorder \| 3 C0042109 \| hives \| 2 C0024314 \| lymphoproliferative disorders \| 2 C0009763 \| conjunctivitis \| 2 C0035455 \| rhinitis \| 2 C0015230 \| rash \| 2 C0019158 \| hepatitis \| 2 C0409974 \| lupus erythematosus \| 2 C0024141 \| systemic lupus erythematosus \| 2 C0032285 \| pneumoniae \| 1 C0013182 \| drug hypersensitivity \| 1 C0024530 \| malaria \| 1 C0023434 \| small lymphocytic lymphoma \| 1 C0007134 \| renal cell cancer \| 1 C0035078 \| renal failure \| 1 C0020538 \| hypertension \| 1 C0263666 \| juvenile dermatomyositis \| 1 C0003872 \| psoriatic arthritis \| 1 C0023434 \| lymphocytic lymphoma \| 1 C0002878 \| haemolytic anaemia \| 1 C0026850 \| progressive muscular dystrophy \| 1 C0272126 \| evans syndrome \| 1 C0011633 \| dermatomyositis \| 1 C0027022 \| myeloproliferative disorder \| 1 C0042109 \| urticarial \| 1 C0024299 \| lymphoma \| 1 C0027022 \| myeloproliferative disorders \| 1 C0019196 \| hepatitis c \| 1 C0085642 \| livedo reticularis \| 1 C0010346 \| crohn's disease \| 1 C0011849 \| diabetes mellitus \| 1 C0159069 \| impaired glucose tolerance \| 1 C0024897 \| mastocytoma \| 1 C0011860 \| type 2 diabetes \| 1 C0004096 \| asthma \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:10) HLA-DRB1 \| 3123 \| CTD_human PLAT \| 5327 \| CTD_human HLA-DPB1 \| 3115 \| CTD_human ALB \| 213 \| CTD_human IFT43 \| 112752 \| GWASCAT HLA-DQB1 \| 3119 \| CTD_human F12 \| 2161 \| GHR ABI3BP \| 25890 \| GWASCAT SERPING1 \| 710 \| GHR XPNPEP2 \| 7512 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:3) 1636 \| ACE \| infer 624 \| BDKRB2 \| infer 7512 \| XPNPEP2 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:101) 2191 \| FAP \| DISEASES 623 \| BDKRB1 \| DISEASES 479 \| ATP12A \| DISEASES 6361 \| CCL17 \| DISEASES 5327 \| PLAT \| DISEASES 973 \| CD79A \| DISEASES 708 \| C1QBP \| DISEASES 3567 \| IL5 \| DISEASES 718 \| C3 \| DISEASES 5199 \| CFP \| DISEASES 1215 \| CMA1 \| DISEASES 3848 \| KRT1 \| DISEASES 2161 \| F12 \| DISEASES 1401 \| CRP \| DISEASES 967 \| CD63 \| DISEASES 114294 \| LACTB \| DISEASES 8731 \| RNMT \| DISEASES 495 \| ATP4A \| DISEASES 8578 \| SCARF1 \| DISEASES 5588 \| PRKCQ \| DISEASES 9424 \| KCNK6 \| DISEASES 8916 \| HERC3 \| DISEASES 3818 \| KLKB1 \| DISEASES 3827 \| KNG1 \| DISEASES 8547 \| FCN3 \| DISEASES 5972 \| REN \| DISEASES 185 \| AGTR1 \| DISEASES 710 \| SERPING1 \| DISEASES 2206 \| MS4A2 \| DISEASES 3176 \| HNMT \| DISEASES 51594 \| NBAS \| DISEASES 84539 \| MCHR2 \| DISEASES 25890 \| ABI3BP \| DISEASES 351 \| APP \| DISEASES 715 \| C1R \| DISEASES 1636 \| ACE \| DISEASES 2220 \| FCN2 \| DISEASES 4056 \| LTC4S \| DISEASES 23498 \| HAAO \| DISEASES 152185 \| SPICE1 \| DISEASES 213 \| ALB \| DISEASES 5648 \| MASP1 \| DISEASES 6037 \| RNASE3 \| DISEASES 10421 \| CD2BP2 \| DISEASES 624 \| BDKRB2 \| DISEASES 2147 \| F2 \| DISEASES 5340 \| PLG \| DISEASES 9092 \| SART1 \| DISEASES 64236 \| PDLIM2 \| DISEASES 6863 \| TAC1 \| DISEASES 5345 \| SERPINF2 \| DISEASES 2 \| A2M \| DISEASES 9622 \| KLK4 \| DISEASES 716 \| C1S \| DISEASES 6401 \| SELE \| DISEASES 2152 \| F3 \| DISEASES 3320 \| HSP90AA1 \| DISEASES 114548 \| NLRP3 \| DISEASES 1368 \| CPM \| DISEASES 1003 \| CDH5 \| DISEASES 728 \| C5AR1 \| DISEASES 5265 \| SERPINA1 \| DISEASES 3084 \| NRG1 \| DISEASES 5336 \| PLCG2 \| DISEASES 4311 \| MME \| DISEASES 1803 \| DPP4 \| DISEASES 5742 \| PTGS1 \| DISEASES 1378 \| CR1 \| DISEASES 5743 \| PTGS2 \| DISEASES 462 \| SERPINC1 \| DISEASES 1805 \| DPT \| DISEASES 2205 \| FCER1A \| DISEASES 1369 \| CPN1 \| DISEASES 255631 \| COL24A1 \| DISEASES 959 \| CD40LG \| DISEASES 5236 \| PGM1 \| DISEASES 7512 \| XPNPEP2 \| DISEASES 5203 \| PFDN4 \| DISEASES 186 \| AGTR2 \| DISEASES 10800 \| CYSLTR1 \| DISEASES 80114 \| BICC1 \| DISEASES 8928 \| FOXH1 \| DISEASES 23177 \| CEP68 \| DISEASES 5212 \| VIT \| DISEASES 114805 \| GALNT13 \| DISEASES 5547 \| PRCP \| DISEASES 26091 \| HERC4 \| DISEASES 3269 \| HRH1 \| DISEASES 10747 \| MASP2 \| DISEASES 2160 \| F11 \| DISEASES 6915 \| TBXA2R \| DISEASES 85443 \| DCLK3 \| DISEASES 720 \| C4A \| DISEASES 117579 \| RLN3 \| DISEASES 9278 \| ZBTB22 \| DISEASES 721 \| C4B \| DISEASES 23194 \| FBXL7 \| DISEASES 22999 \| RIMS1 \| DISEASES 4637 \| MYL6 \| DISEASES 387521 \| TMEM189 \| DISEASES 102723508 \| KANTR \| DISEASES
Locus	(Waiting for update.)

Disease ID	381
Disease	angioedema
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:44) HP:0001025 \| Hives \| 26 HP:0001880 \| Eosinophilia \| 14 HP:0012531 \| Pain \| 4 HP:0005523 \| Lymphoproliferative disorder \| 3 HP:0000988 \| Exanthem \| 2 HP:0000509 \| Conjunctivitis \| 2 HP:0002725 \| Systemic lupus erythematosus \| 2 HP:0000989 \| pruritis \| 2 HP:0001297 \| Cerebral vascular events \| 2 HP:0003326 \| Muscle pain \| 2 HP:0002781 \| Upper airway obstruction \| 2 HP:0000158 \| Abnormally large tongue \| 2 HP:0012115 \| Liver inflammation \| 2 HP:0000969 \| Dropsy \| 2 HP:0002027 \| Abdominal pain \| 2 HP:0012384 \| Nasal inflammation \| 2 HP:0002615 \| Low blood pressure \| 2 HP:0002013 \| Emesis \| 1 HP:0012027 \| Laryngeal edema \| 1 HP:0000083 \| Renal insufficiency \| 1 HP:0002098 \| Respiratory distress \| 1 HP:0100749 \| Thoracic pain \| 1 HP:0001878 \| Haemolytic anaemia \| 1 HP:0030828 \| Wheezing \| 1 HP:0002665 \| Lymphoma \| 1 HP:0200123 \| Chronic liver inflammation \| 1 HP:0005547 \| Myeloproliferative disorder \| 1 HP:0100280 \| Morbus Crohn \| 1 HP:0001541 \| Ascites \| 1 HP:0000822 \| Hypertension \| 1 HP:0012393 \| Allergy \| 1 HP:0001945 \| Fever \| 1 HP:0010783 \| Erythema \| 1 HP:0000965 \| Livedo reticularis \| 1 HP:0005945 \| Laryngeal obstruction \| 1 HP:0000833 \| Glucose intolerance \| 1 HP:0012735 \| Coughing \| 1 HP:0002099 \| Asthma \| 1 HP:0001941 \| acidemia \| 1 HP:0200119 \| Acute liver inflammation \| 1 HP:0002357 \| Dysphasia \| 1 HP:0005110 \| Atrial fibrillation \| 1 HP:0012418 \| Low blood oxygen level \| 1 HP:0000819 \| Diabetes mellitus \| 1

Disease ID	381
Disease	angioedema
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:2)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs9323624	24236485	112752	IFT43	umls:C0002994	GWASCAT	Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations.	0.12	2014	IFT43	14	76033960	T	C
rs9833094	24236485	25890	ABI3BP	umls:C0002994	GWASCAT	Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations.	0.12	2014	ABI3BP	3	100872081	C	T

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:182)
CHR	POS	SNPID	REF	ALT	ORI_SNPID	PMID	P_VALUE	P_VALUE_TEXT	OR/BETA	CI95_TEXT	GWAS_INITIAL_SAMPLE_SIZE	SUB_POPULATION	SUPER_POPULATION	GWAS_TRAIT	HPO_ID	HPO_TERM	DO_ID	DO_TERM	MESH_ID	MESH_TERM	EFO_ID	EFO_TERM	DOLITE_TERM	RISK_ALLELE	PUBLICATION_TYPE	AA	GENE_SYMBOL	TYPE	REFGENE
1	7541345	rs2796483	C	T	rs2796483	24236485	9.70E-05	(EA)	2.07	[1.43-2.99]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	7552326	rs1750849	G	C	rs1750849	24236485	4.30E-05	(EA)	2.13	[1.48-3.08]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	66518697	rs2503222	C	T	rs2503222	24236485	2.58E-05	(East Asian)	4.8	[2.19-10.52]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	66529821	rs1500963	G	A	rs1500963	24236485	2.58E-05	(East Asian)	4.8	[2.19-10.52]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	78805511	rs12064888	A	G	rs12064888	24236485	5.30E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	86464262	rs10873740	T	C	rs10873740	24236485	8.52E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	86464981	rs11161717	A	G	rs11161717	24236485	8.52E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	105720963	rs4601631	A	C	rs4601631	24236485	8.93E-05	(EA)	2.04	[1.41-2.94]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	116017908	rs9429756	A	G	rs9429756	23838604	8.85E-05	Additive model, African Americans	2.44	[1.56-3.82]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs9429756-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
1	185440175	rs17643861	G	A	rs17643861	24236485	7.09E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	195376935	rs1324713	C	T	rs1324713	24236485	2.09E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	195376972	rs6702266	C	T	rs6702266	24236485	3.65E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	205859798	rs12028467	G	C	rs12028467	24236485	6.86E-05	(East Asian)	2.61	[1.64-4.14]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	233279349	rs1125642	G	A	rs1125642	24236485	3.61E-05	(East Asian)	2.52	[1.63-3.89]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	233279349	rs1125642	G	A	rs1125642	24236485	9.76E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	240679670	rs12143400	T	C	rs12143400	24236485	4.87E-05	(East Asian)	2.25	[1.46-3.46]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	245768212	rs1715794	C	T	rs1715794	24236485	1.75E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
1	245768212	rs1715794	C	T	rs1715794	24236485	3.90E-05	(East Asian)	2.4	[1.59-3.64]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	4344241	rs10171541	A	G	rs10171541	24236485	6.88E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	30237620	rs7575487	T	G	rs7575487	23838604	7.21E-05	Additive model, European Americans	1.96	[1.41-2.74]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs7575487-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
2	50328375	rs13430861	C	A	rs13430861	24236485	5.70E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	50330318	rs17039291	T	A	rs17039291	24236485	8.47E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	50357734	rs7606758	T	C	rs7606758	24236485	7.14E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	50358675	rs13008902	T	G	rs13008902	24236485	3.68E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	144820057	rs4662366	A	G	rs4662366	24236485	9.17E-05	(East Asian)	2.32	[1.51-3.57]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	154889520	rs7565078	G	T	rs7565078	24236485	4.47E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	154961754	rs12693918	G	T	rs12693918	24236485	9.75E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	181025248	rs1401105	A	G	rs1401105	23838604	9.71E-05	Additive model, African Americans	2.53	[1.59-4.04]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs1401105-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
2	181027688	rs6433833	T	C	rs6433833	23838604	3.14E-05	Additive model, African Americans	2.86	[1.74-4.69]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs6433833-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
2	181975252	rs7569991	T	G	rs7569991	23838604	5.48E-05	Additive model, European Americans	2.13	[1.47-3.03]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
2	206541927	rs6756429	T	C	rs6756429	24236485	8.76E-05	(EA)	2.03	[1.41-2.93]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
2	211981461	rs17737064	T	A	rs17737064	24236485	5.54E-05	(East Asian)	2.38	[1.57-3.59]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	6230553	rs12374158	G	T	rs12374158	23838604	1.85E-05	Additive model, European Americans	3.31	[1.91-5.71]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs12374158-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
3	68065895	rs9857691	C	G	rs9857691	24236485	6.32E-05	(EA)	2.31	[1.56-3.42]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	96308055	rs7631577	G	T	rs7631577	23838604	3.59E-05	Additive model, European Americans	2.06	[1.46-2.91]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs7631577-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
3	100571493	rs4928089	G	A	rs4928089	24236485	1.35E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100571493	rs4928089	G	A	rs4928089	24236485	2.12E-06	(East Asian)	2.82	[1.80-4.44]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100588943	rs12330531	T	A	rs12330531	24236485	2.90E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100588943	rs12330531	T	A	rs12330531	24236485	9.38E-07	(East Asian)	2.87	[1.83-4.52]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100589330	rs1116931	C	A	rs1116931	24236485	3.07E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100589330	rs1116931	C	A	rs1116931	24236485	8.39E-07	(East Asian)	2.93	[1.86-4.62]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100590925	rs9833094	C	T	rs9833094	24236485	2.00E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	100590925	rs9833094	C	T	rs9833094	24236485	5.00E-07	(East Asian)	2.95	[1.88-4.64]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	122650890	rs13099843	A	C	rs13099843	23838604	4.18E-05	Additive model, European Americans	2.56	NA	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
3	131733286	rs1122856	G	A	rs1122856	23838604	2.30E-05	Additive model, European Americans	2.08	[1.48-2.93]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs1122856-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
3	161649352	rs6441417	G	A	rs6441417	24236485	3.32E-05	(EA)	3.69	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
3	161649516	rs6441418	A	C	rs6441418	24236485	2.91E-05	(EA)	3.67	[1.97-6.82]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
4	42948976	rs4861238	G	T	rs4861238	23838604	8.62E-05	Additive model, European Americans	2.12	[1.46-3.09]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4861238-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
4	48495577	rs13114836	C	G	rs13114836	24236485	6.91E-05	(EA)	2.62	[1.62-4.22]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
4	90186759	rs6532150	G	A	rs6532150	24236485	5.13E-05	(EA)	10.81	[2.51-46.50]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
4	102432702	rs890448	C	T	rs890448	24236485	8.00E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
4	102432702	rs890448	C	T	rs890448	24236485	9.28E-05	(East Asian)	2.13	[1.45-3.13]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
4	181310204	rs10780063	A	G	rs10780063	24236485	3.46E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
5	15723346	rs11748700	A	G	rs11748700	24236485	2.37E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
5	15735014	rs4289558	A	G	rs4289558	24236485	5.05E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
5	36137620	rs267759	A	G	rs267759	24236485	7.58E-05	(East Asian)	2.23	[1.48-3.37]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
5	97929966	rs461409	C	T	rs461409	24236485	3.00E-06	(EA)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
5	111300851	rs4957995	G	A	rs4957995	23838604	1.48E-06	Additive model, European Americans	4.31	[2.38-7.82]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4957995-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
5	111480534	rs17134154	T	C	rs17134154	23838604	4.83E-05	Dominant model, European Americans	2.63	[1.65-4.19]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs17134154-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
5	148312767	rs7729953	T	C	rs7729953	23838604	1.37E-05	Dominant model, African Americans	5.56	[2.56-12.50]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
6	41240171	rs16894387	A	C	rs16894387	23838604	4.73E-05	Additive model, European Americans	2.23	[1.52-3.28]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs16894387-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
6	56884451	rs2167460	T	C	rs2167460	23838604	5.45E-05	Dominant model, European Americans	2.78	[1.69-4.76]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
6	56900340	rs4715646	T	C	rs4715646	23838604	1.17E-05	Additive model, European Americans	3.03	NA	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
6	72905741	rs2496515	A	G	rs2496515	24236485	5.63E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	72906753	rs2249625	A	G	rs2249625	24236485	2.17E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	72906753	rs2249625	A	G	rs2249625	24236485	5.00E-06	(EA)	2.24	[1.55-3.24]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	72918148	rs2463749	G	C	rs2463749	24236485	6.80E-05	(EA)	2.04	[1.41-2.95]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	72920943	rs2254147	C	G	rs2254147	24236485	5.04E-05	(EA)	2.06	[1.43-2.98]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	88433865	rs2754273	T	C	rs2754273	24236485	8.17E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	132845928	rs1001859	C	T	rs1001859	24236485	9.42E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
6	151319827	rs561060	C	T	rs561060	23838604	8.86E-05	Additive model, European Americans	1.94	[1.39-2.70]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs561060-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
7	17089962	rs4721564	C	T	rs4721564	24236485	7.68E-05	(EA)	2.11	[1.44-3.07]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
7	103595652	rs722277	C	T	rs722277	23838604	5.89E-05	Additive model, European Americans	2.03	[1.44-2.86]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs722277-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
7	103598671	rs6943822	T	C	rs6943822	23838604	6.54E-05	Recessive model, European Americans	3.06	[1.77-5.30]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs6943822-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
7	103637906	rs6955789	G	A	rs6955789	23838604	3.18E-05	Additive model, European Americans	2.33	[1.56-3.45]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
7	103771201	rs194844	A	C	rs194844	23838604	3.98E-05	Additive model, European Americans	2.13	[1.47-3.03]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
7	118709754	rs10238286	T	G	rs10238286	23838604	5.21E-05	Additive model, African Americans	2.45	[1.59-3.79]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs10238286-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
8	2513884	rs9314462	T	C	rs9314462	24236485	5.30E-05	(EA)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
8	75707662	rs7842758	A	G	rs7842758	24236485	6.25E-05	(EA)	3.11	[1.76-5.50]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
8	126611047	rs17330462	T	C	rs17330462	24236485	4.37E-05	(East Asian)	2.82	[1.71-4.67]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
8	126612515	rs7017801	A	G	rs7017801	24236485	4.37E-05	(East Asian)	2.82	[1.71-4.67]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
8	126614369	rs10956253	C	T	rs10956253	24236485	4.37E-05	(East Asian)	2.82	[1.71-4.67]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
8	129836728	rs6996572	C	T	rs6996572	23838604	8.26E-05	Dominant model, African Americans	6.17	[2.49-15.29]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs6996572-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
9	10481205	rs1853232	C	T	rs1853232	24236485	8.14E-05	(East Asian)	3.27	[1.76-6.07]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	11397008	rs2065746	T	G	rs2065746	24236485	6.46E-05	(East Asian)	2.11	[1.44-3.09]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	11408193	rs10809464	T	A	rs10809464	24236485	6.59E-05	(East Asian)	2.11	[1.44-3.10]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	11419061	rs1335467	T	G	rs1335467	24236485	9.42E-05	(East Asian)	2.07	[1.41-3.02]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	11423524	rs1335464	C	G	rs1335464	24236485	9.42E-05	(East Asian)	2.07	[1.41-3.02]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	11437634	rs9406426	C	T	rs9406426	24236485	8.02E-05	(East Asian)	2.07	[1.41-3.02]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	12272803	rs6474695	G	A	rs6474695	24236485	4.24E-05	(East Asian)	2.19	[1.49-3.20]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	12272803	rs6474695	G	A	rs6474695	24236485	5.79E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	13106598	rs3264	T	C	rs3264	23838604	8.31E-05	Additive model, European Americans	1.94	[1.39-2.70]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs3264-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
9	75564954	rs8187876	C	T	rs8187876	23838604	2.41E-06	Dominant model, African Americans	4.42	[2.38-8.19]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs8187876-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
9	75586627	rs10156653	C	T	rs10156653	23838604	4.21E-06	Dominant model, African Americans	4.24	[2.29-7.84]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs10156653-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
9	93561309	rs290992	T	C	rs290992	24236485	9.83E-05	(East Asian)	2.2	[1.47-3.30]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
9	121326894	rs4404982	A	G	rs4404982	23838604	3.06E-05	Dominant model, European Americans	3.79	[2.03-7.08]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4404982-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
10	1478900	rs17156347	T	A	rs17156347	24236485	8.52E-05	(East Asian)	3.1	[1.71-5.64]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	6550590	rs500766	C	T	rs500766	23838604	2.97E-05	Additive model, European Americans	2.38	[1.59-3.57]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
10	6564775	rs667254	C	T	rs667254	23838604	2.97E-05	Additive model, European Americans	2.38	[1.59-3.57]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
10	7623127	rs12774458	G	A	rs12774458	24236485	1.92E-05	(East Asian)	2.91	[1.79-4.74]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	8202956	rs17376977	C	A	rs17376977	23838604	5.61E-05	Additive model, European Americans	2.33	[1.54-3.51]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs17376977-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
10	11874754	rs11257350	C	T	rs11257350	24236485	4.50E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	60626234	rs3125447	A	G	rs3125447	24236485	4.77E-05	(EA)	2.8	[1.74-4.50]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	60643336	rs282674	A	G	rs282674	24236485	1.17E-05	(EA)	3.02	[1.86-4.90]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	60643336	rs282674	A	G	rs282674	24236485	6.92E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	60643617	rs282673	G	A	rs282673	24236485	1.82E-05	(EA)	2.96	[1.83-4.82]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
10	72513272	rs4747095	G	A	rs4747095	24236485	8.37E-05	(EA)	2.52	[1.58-4.00]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
11	8262401	rs3849994	A	G	rs3849994	23838604	9.09E-05	Additive model, African Americans	2.52	[1.59-4.01]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs3849994-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
11	8266559	rs2061036	C	T	rs2061036	23838604	5.05E-06	Additive model, African Americans	3.43	[2.02-5.82]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs2061036-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
11	11596478	rs11021941	T	C	rs11021941	23838604	5.94E-05	Additive model, African Americans	2.46	[1.57-3.81]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs11021941-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
11	44075714	rs4237645	T	C	rs4237645	23838604	3.78E-05	Recessive model, European Americans	3.33	[1.88-5.89]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4237645-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
11	78915775	rs1938821	C	T	rs1938821	24236485	6.21E-05	(East Asian)	2.28	[1.53-3.41]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
11	80982032	rs2199021	A	G	rs2199021	24236485	4.79E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
11	132938574	rs2060123	C	T	rs2060123	23838604	6.60E-05	Additive model, European Americans	2	[1.42-2.81]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs2060123-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	1050254	rs7311151	G	A	rs7311151	23838604	7.95E-05	Additive model, European Americans	1.93	[1.39-2.68]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs7311151-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	1357650	rs12426509	T	G	rs12426509	24236485	7.17E-05	(EA)	2.1	[1.43-3.07]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
12	3757923	rs758530	A	G	rs758530	23838604	1.00E-06	Additive model, European Americans	2.34	[1.67-3.30]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs758530-C	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	3772977	rs1015762	T	C	rs1015762	23838604	5.18E-06	Dominant model, European Americans	2.86	[1.82-4.49]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs1015762-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	11888423	rs2051525	A	G	rs2051525	23838604	6.01E-05	Additive model, African Americans	2.5	NA	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	11899973	rs2724635	G	A	rs2724635	23838604	2.73E-05	Additive model, African Americans	2.78	NA	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs2724635-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	67476327	rs17781082	C	T	rs17781082	23838604	9.31E-05	Additive model, European Americans	1.94	[1.39-2.71]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs17781082-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
12	75925402	rs11610328	A	G	rs11610328	24236485	9.48E-05	(East Asian)	5.63	[2.41-13.15]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
12	75969345	rs2700521	A	G	rs2700521	24236485	9.48E-05	(East Asian)	5.63	[2.41-13.15]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
12	75991446	rs2054517	C	A	rs2054517	24236485	9.48E-05	(East Asian)	5.63	[2.41-13.15]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
12	94621058	rs2291333	T	C	rs2291333	23838604	6.61E-05	Additive model, European Americans	2.54	[1.61-4.02]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs2291333-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
13	28996960	rs10507385	T	C	rs10507385	24236485	9.84E-05	(East Asian)	2.8	[1.72-4.57]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	40039652	rs12873765	C	T	rs12873765	24236485	9.66E-05	(East Asian)	2.11	[1.44-3.09]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	40039812	rs10492737	C	T	rs10492737	24236485	6.65E-05	(East Asian)	2.16	[1.47-3.16]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	40039932	rs10492736	A	G	rs10492736	24236485	6.65E-05	(East Asian)	2.16	[1.47-3.16]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	40040036	rs10492735	A	G	rs10492735	24236485	6.65E-05	(East Asian)	2.16	[1.47-3.16]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	40040314	rs10492734	C	T	rs10492734	24236485	6.65E-05	(East Asian)	2.16	[1.47-3.16]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	72337943	rs7139667	C	T	rs7139667	23838604	5.42E-05	Additive model, African Americans	2.57	[1.62-4.05]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs7139667-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
13	105701736	rs3935930	G	A	rs3935930	24236485	6.64E-05	(EA)	8.53	[2.51-29.02]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	110679470	rs2225777	T	A	rs2225777	24236485	5.29E-05	(EA)	2.13	[1.47-3.09]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	110680944	rs1335807	A	G	rs1335807	24236485	8.89E-05	(EA)	2.11	[1.46-3.06]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	110681212	rs1029204	A	G	rs1029204	24236485	7.97E-05	(EA)	2.1	[1.45-3.04]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
13	110688140	rs1335808	A	T	rs1335808	24236485	4.26E-05	(EA)	2.12	[1.47-3.06]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	46750607	rs10137970	A	G	rs10137970	23838604	1.81E-05	Additive model, European Americans	2.9	[1.78-4.72]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs10137970-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
14	46789696	rs12437173	A	G	rs12437173	23838604	2.84E-05	Additive model, European Americans	2.87	[1.75-4.71]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs12437173-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
14	68747868	rs7148416	A	T	rs7148416	24236485	1.74E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	68749927	rs3784099	G	A	rs3784099	24236485	2.23E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	68749927	rs3784099	G	A	rs3784099	24236485	7.10E-05	(EA)	2.15	[1.48-3.13]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	68752643	rs8008961	C	T	rs8008961	24236485	6.00E-06	(EA)	2.44	[1.67-3.56]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	68864311	rs4899241	T	C	rs4899241	24236485	9.46E-05	(EA)	2.25	[1.52-3.33]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	76500303	rs9323624	T	C	rs9323624	24236485	1.00E-06	(East Asian)	2.88	[1.84-4.51]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	76500303	rs9323624	T	C	rs9323624	24236485	1.30E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	76561318	rs8011069	G	A	rs8011069	24236485	6.43E-05	(East Asian)	2.86	[1.69-4.82]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	78960255	rs1544623	A	G	rs1544623	24236485	9.57E-05	(East Asian)	2.17	[1.48-3.18]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	79016165	rs10483907	G	A	rs10483907	24236485	5.22E-05	(East Asian)	2.32	[1.57-3.41]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	81643800	rs4899786	G	T	rs4899786	23838604	8.14E-05	Additive model, European Americans	2.18	[1.48-3.22]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4899786-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
14	81677454	rs7142641	A	G	rs7142641	23838604	8.14E-05	Additive model, European Americans	2.18	[1.48-3.22]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs7142641-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
14	93840193	rs6575330	A	G	rs6575330	24236485	9.40E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
14	96611391	rs12888576	A	G	rs12888576	23838604	6.57E-05	Additive model, European Americans	2.56	NA	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
15	40700022	rs10518693	C	T	rs10518693	23838604	4.01E-05	Recessive model, European Americans	3.17	[1.83-5.49]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs10518693-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
15	40717302	rs2034650	G	A	rs2034650	23838604	3.65E-06	Dominant model, European Americans	3.03	[1.89-4.76]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
15	86863911	rs1353577	G	A	rs1353577	24236485	8.59E-05	(East Asian)	2.14	[1.44-3.18]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
15	86864635	rs12437556	C	T	rs12437556	24236485	1.17E-05	(East Asian)	2.42	[1.60-3.65]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
15	86864635	rs12437556	C	T	rs12437556	24236485	8.91E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
15	94432246	rs4335731	G	A	rs4335731	23838604	3.61E-05	Dominant model, European Americans	2.81	[1.72-4.59]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs4335731-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
15	96858409	rs4310804	C	G	rs4310804	24236485	9.34E-05	(East Asian)	2.2	[1.50-3.23]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
16	17177321	rs1391351	A	G	rs1391351	24236485	8.93E-05	(East Asian)	4.8	[1.96-11.75]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
16	87461969	rs9646303	G	A	rs9646303	24236485	1.15E-05	(EA)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
17	14542140	rs11652573	G	A	rs11652573	24236485	2.73E-05	(East Asian)	2.83	[1.70-4.71]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
17	14549642	rs16950131	C	T	rs16950131	24236485	4.68E-05	(East Asian)	2.72	[1.64-4.50]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
17	53356126	rs4617927	G	T	rs4617927	24236485	4.22E-06	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
17	53361838	rs1477141	T	G	rs1477141	24236485	5.79E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
17	53808795	rs17758328	C	A	rs17758328	23838604	2.16E-05	Additive model, European Americans	3.04	[1.82-5.08]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs17758328-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
19	22789430	rs11673496	G	A	rs11673496	24236485	1.75E-05	(EA)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
19	39792460	rs194014	G	A	rs194014	23838604	2.59E-05	Dominant model, African Americans	4	[2.08-7.69]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
19	56931672	rs917650	C	T	rs917650	24236485	4.37E-05	(East Asian)	3.62	[1.90-6.91]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	20150027	rs6075630	C	T	rs6075630	24236485	2.45E-05	(EA)	2.98	[1.80-4.94]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	20150027	rs6075630	C	T	rs6075630	24236485	2.66E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	20158867	rs6106205	T	C	rs6106205	24236485	4.08E-05	(EA)	2.83	[1.74-4.60]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	20158867	rs6106205	T	C	rs6106205	24236485	4.27E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	43893582	rs6094118	G	A	rs6094118	24236485	1.11E-05	(meta-analysis of East Asian and European Ancestry)	NA	NA	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
20	54831274	rs6069674	C	T	rs6069674	24236485	5.43E-05	(East Asian)	2.33	[1.54-3.52]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
21	37807852	rs9981659	G	A	rs9981659	23838604	5.32E-05	Dominant model, European Americans	2.58	[1.63-4.08]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs9981659-A	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
21	37809377	rs9984974	A	G	rs9984974	23838604	5.95E-05	Additive model, European Americans	2.56	[1.62-4.06]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs9984974-G	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
21	37809408	rs9985126	C	T	rs9985126	23838604	5.32E-05	Dominant model, European Americans	2.58	[1.63-4.08]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	rs9985126-T	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
22	28178948	rs12158991	G	A	rs12158991	24236485	8.49E-05	(East Asian)	10.25	[2.38-44.18]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease
22	42688724	rs17002948	T	G	rs17002948	23838604	5.45E-05	Dominant model, African Americans	7.69	[2.78-20.00]	175 ACE inhibitor-associated angioedema cases; 489 ACE inhibitor-exposed controls	NOPOP(664)	ALL(664)	NOPOP(664)	ALL(664)	Angioedema in response to angiotensin-converting enzyme inhibitor	HPOID:0100665	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease	NA	Randomized Controlled Trial	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't
22	49067053	rs2057204	A	G	rs2057204	24236485	7.16E-05	(EA)	2.31	[1.51-3.52]	112 European ancestry cases; 124 European ancestry controls; 120 Han Chinese ancestry cases; 101 Han Chinese ancestry controls	Han Chinese(221)	European(236)	ALL(457)	ASN(221)	EUR(236)	ALL(457)	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HPOID:0001025	HPOID:0100665	Urticaria	Angioedema	DOID:1558	angioedema	NA	NA	NA	NA	Skin disease

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:61)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0002994	acetaminophen	D000082	103-90-2	angioedema	MESH:D000799	marker/mechanism	10982225
C0002994	acetaminophen	D000082	103-90-2	angioedema	MESH:D000799	therapeutic	20689124
C0002994	acetylcysteine	D000111	616-91-1	angioedema	MESH:D000799	marker/mechanism	11736926
C0002994	alprazolam	D000525	28981-97-7	angioedema	MESH:D000799	marker/mechanism	16987489
C0002994	aminocaproic acid	D015119	60-32-2	angioedema	MESH:D000799	therapeutic	6533528
C0002994	amlodipine	D017311	88150-42-9	angioedema	MESH:D000799	marker/mechanism	12671332
C0002994	benazepril	C044946	86541-75-5	angioedema	MESH:D000799	marker/mechanism	17285209
C0002994	carbamazepine	D002220	298-46-4	angioedema	MESH:D000799	marker/mechanism	11507366
C0002994	celecoxib	D000068579	-	angioedema	MESH:D000799	marker/mechanism	15859361
C0002994	chloramphenicol	D002701	56-75-7	angioedema	MESH:D000799	marker/mechanism	3994402
C0002994	chloroquine	D002738	1954/5/7	angioedema	MESH:D000799	marker/mechanism	18343736
C0002994	chlorthalidone	D002752	77-36-1	angioedema	MESH:D000799	marker/mechanism	16957427
C0002994	cimetidine	D002927	51481-61-9	angioedema	MESH:D000799	marker/mechanism	4078029
C0002994	ciprofloxacin	D002939	85721-33-1	angioedema	MESH:D000799	marker/mechanism	7596948
C0002994	clozapine	D003024	5786-21-0	angioedema	MESH:D000799	marker/mechanism	17189753
C0002994	cromolyn sodium	D004205	15826-37-6	angioedema	MESH:D000799	therapeutic	6814739
C0002994	diclofenac	D004008	15307-86-5	angioedema	MESH:D000799	marker/mechanism	15321629
C0002994	calcitriol	D002117	32222-06-3	angioedema	MESH:D000799	marker/mechanism	9893204
C0002994	diltiazem	D004110	42399-41-7	angioedema	MESH:D000799	marker/mechanism	19299323
C0002994	doxazosin	D017292	74191-85-8	angioedema	MESH:D000799	marker/mechanism	16957427
C0002994	droperidol	D004329	548-73-2	angioedema	MESH:D000799	marker/mechanism	8155111
C0002994	enalapril	D004656	75847-73-3	angioedema	MESH:D000799	marker/mechanism	11129038
C0002994	epirubicin	D015251	56420-45-2	angioedema	MESH:D000799	marker/mechanism	9218739
C0002994	etomidate	D005045	33125-97-2	angioedema	MESH:D000799	marker/mechanism	3578739
C0002994	everolimus	D000068338	-	angioedema	MESH:D000799	marker/mechanism	15849555
C0002994	fenoprofen	D005279	31879-05-7	angioedema	MESH:D000799	marker/mechanism	1115460
C0002994	fluconazole	D015725	86386-73-4	angioedema	MESH:D000799	marker/mechanism	1679171
C0002994	fluorouracil	D005472	51-21-8	angioedema	MESH:D000799	marker/mechanism	3719553
C0002994	fluoxetine	D005473	54910-89-3	angioedema	MESH:D000799	marker/mechanism	2628588
C0002994	fosinopril	D017328	98048-97-6	angioedema	MESH:D000799	marker/mechanism	11773949
C0002994	indomethacin	D007213	53-86-1	angioedema	MESH:D000799	marker/mechanism	1115460
C0002994	isradipine	D017275	75695-93-1	angioedema	MESH:D000799	marker/mechanism	19077729
C0002994	ketorolac	D020910	66635-83-4	angioedema	MESH:D000799	marker/mechanism	8189303
C0002994	lidocaine	D008012	137-58-6	angioedema	MESH:D000799	marker/mechanism	17537275
C0002994	loratadine	D017336	79794-75-5	angioedema	MESH:D000799	therapeutic	10188144
C0002994	lovastatin	D008148	75330-75-5	angioedema	MESH:D000799	marker/mechanism	10084510
C0002994	methotrexate	D008727	1959/5/2	angioedema	MESH:D000799	marker/mechanism	10515658
C0002994	metoprolol	D008790	37350-58-6	angioedema	MESH:D000799	marker/mechanism	12671332
C0002994	montelukast	C093875	158966-92-8	angioedema	MESH:D000799	therapeutic	10982225
C0002994	nisoldipine	D015737	63675-72-9	angioedema	MESH:D000799	marker/mechanism	19077729
C0002994	omeprazole	D009853	73590-58-6	angioedema	MESH:D000799	marker/mechanism	12464168
C0002994	phenytoin	D010672	57-41-0	angioedema	MESH:D000799	marker/mechanism	6071477
C0002994	piroxicam	D010894	36322-90-4	angioedema	MESH:D000799	marker/mechanism	14682198
C0002994	progesterone	D011374	57-83-0	angioedema	MESH:D000799	marker/mechanism	18302843
C0002994	propranolol	D011433	525-66-6	angioedema	MESH:D000799	marker/mechanism	20592324
C0002994	ramipril	D017257	87333-19-5	angioedema	MESH:D000799	marker/mechanism	12126067
C0002994	rofecoxib	C116926	-	angioedema	MESH:D000799	marker/mechanism	15702813
C0002994	sirolimus	D020123	53123-88-9	angioedema	MESH:D000799	marker/mechanism	15147436
C0002994	succinylcholine	D013390	306-40-1	angioedema	MESH:D000799	marker/mechanism	5495061
C0002994	tacrolimus	D016559	109581-93-3	angioedema	MESH:D000799	marker/mechanism	17377381
C0002994	terfenadine	D016593	50679-08-8	angioedema	MESH:D000799	therapeutic	12373280
C0002994	thiethylperazine	D013847	1420-55-9	angioedema	MESH:D000799	marker/mechanism	16101941
C0002994	thiopental	D013874	76-75-5	angioedema	MESH:D000799	marker/mechanism	1166949
C0002994	ticlopidine	D013988	55142-85-3	angioedema	MESH:D000799	marker/mechanism	20031738
C0002994	tinidazole	D014011	19387-91-8	angioedema	MESH:D000799	marker/mechanism	6636666
C0002994	tolmetin	D014046	26171-23-3	angioedema	MESH:D000799	marker/mechanism	4006743
C0002994	tramadol	D014147	27203-92-5	angioedema	MESH:D000799	marker/mechanism	15657776
C0002994	trandolapril	C052035	-	angioedema	MESH:D000799	marker/mechanism	12126067
C0002994	tranexamic acid	D014148	1197-18-8	angioedema	MESH:D000799	therapeutic	63691
C0002994	valsartan	D000068756	-	angioedema	MESH:D000799	marker/mechanism	12708991
C0002994	ziprasidone	C092292	146939-27-7	angioedema	MESH:D000799	marker/mechanism	17446198

FDA approved drug and dosage information(Total Drugs:33)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D000799	claritin	loratadine	10MG	TABLET;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	claritin	loratadine	1MG/ML	SYRUP;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	claritin	loratadine	10MG	CAPSULE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	loratadine	loratadine	10MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D000799	loratadine	loratadine	1MG/ML	SUSPENSION;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	nasalcrom	cromolyn sodium	5.2MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SPRAY, METERED;NASAL	Discontinued	None	Yes	No
MESH:D000799	calcijex	calcitriol	0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D000799	mevacor	lovastatin	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D000799	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D000799	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D000799	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D000799	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D000799	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D000799	vioxx	rofecoxib	12.5MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D000799	vioxx	rofecoxib	12.5MG/5ML	SUSPENSION;ORAL	Discontinued	None	No	No
MESH:D000799	vioxx	rofecoxib	12.5MG	TABLET; ORAL	Discontinued	None	No	No
MESH:D000799	rapamune	sirolimus	1MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
MESH:D000799	rapamune	sirolimus	1MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D000799	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D000799	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	None	No	No
MESH:D000799	diovan	valsartan	80MG	CAPSULE;ORAL	Discontinued	None	No	No
MESH:D000799	diovan	valsartan	80MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D000799	afinitor	everolimus	5MG	TABLET;ORAL	Prescription	None	Yes	No
MESH:D000799	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000799	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000799	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000799	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000799	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000799	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000799	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000799	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000799	lysteda	tranexamic acid	650MG	TABLET;ORAL	Prescription	AB	Yes	Yes

FDA labeling changes(Total Drugs:33)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D000799	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D000799	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D000799	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D000799	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D000799	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D000799	03/27/2001	nasalcrom	cromolyn	Prevention and relief of nasal symptoms of hay fever and other nasal allergies	Established proper dose in 2 year - 6 year olds and provided additional safety and compliance data for this age group	Labeling	B	-	-	-	Pharmacia & Upjohn	2/11/1999	FALSE'
MESH:D000799	11/16/2001	calcijex	calcitriol	Management of hypocalcemia in patients undergoing chronic renal dialysis	The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75	Labeling	B	-	-	-	Abbott	02/16/2001	FALSE'
MESH:D000799	02/14/2002	mevacor	lovastatin	Heterozygous Familial Hypercholesterolemia	New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age	Labeling	B	-	-	-	Merck	07/17/2001	FALSE'
MESH:D000799	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D000799	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D000799	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D000799	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D000799	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D000799	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D000799	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'
MESH:D000799	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'
MESH:D000799	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'
MESH:D000799	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D000799	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D000799	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D000799	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D000799	11/29/2007	diovan	valsartan	Hypertension	Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension	Labeling	B	-	-	-	Novartis	8/8/2007	FALSE'
MESH:D000799	11/29/2007	diovan	valsartan	Hypertension	Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension	Labeling	B	-	-	-	Novartis	8/8/2007	FALSE'
MESH:D000799	10/29/2010	afinitor	everolimus	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis	Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication	Labeling	B	-	-	-	Novartis	-	FALSE'
MESH:D000799	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000799	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000799	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000799	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000799	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000799	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000799	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000799	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000799	08/21/2013	lysteda	tranexamic acid	Treatment of cyclic heavy menstrual bleeding	Indicated for women of reproductive age. It is not intended for use in premenarcheal girls Information on PK studyPostmarketing study	-	P	-	-	Ferring	-	FALSE'	-